Survival outcomes among participants with KICS and participants with other KAD. (A) OS among all 43 participants with KICS. (B) OS among 11 participants with KICS and KS who received rituximab with KS-directed therapy. (C) OS of participants by KAD diagnosis, censored at 6 years for all participants.